Safety of anidulafungin in solid organ transplant recipients

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
José María AguadoTOSCANA Study Group

Abstract

The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed. Clinical side effects, liver function tests, and serum creatinine levels were assessed at least weekly. The need for the modification of immunosuppressive drugs was also recorded by the investigators. All patients were followed for at least 1 week after the end of treatment (EOT) or until death. Eighty-six SOT recipients were evaluated (56 transplant recipients, 20 lung transplant recipients, 8 kidney transplant recipients, and 2 heart transplant recipients). Sixty-two patients (72%) received anidulafungin for prophylaxis, and 24 (28%) received anidulafungin for the treatment of IFIs [candidemia/invasive candidiasis (16) or invasive aspergillosis (8)]. At the baseline, only 5% of the patients were neutropenic (<500 neutrophils/mL). There was no need for the modification of immunosuppressive drug doses because of...Continue Reading

References

Apr 9, 1999·Medicine·D L Paterson, N Singh
Mar 5, 2003·Diagnostic Microbiology and Infectious Disease·María del Carmen SerranoEstrella Martín-Mazuelos
Jan 14, 2005·Journal of Clinical Pharmacology·James A DowellIrving E Weston
Jan 18, 2005·Clinical Microbiology Reviews·Nina Singh, David L Paterson
Jun 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose A Vazquez, Jack D Sobel
Feb 27, 2007·Journal of Clinical Pharmacology·James A DowellBharat Damle
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Jul 22, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brahm H SegalBen E De Pauw
Feb 10, 2009·Transplantation·Jesus FortúnUNKNOWN GESITRA Study Group
Mar 12, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasTom M Chiller

❮ Previous
Next ❯

Citations

Nov 6, 2012·Revista brasileira de hematologia e hemoterapia·Marcio Nucci
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N SinghUNKNOWN AST Infectious Diseases Community of Practice
Jan 5, 2014·Journal of Hepatology·Stefano FagiuoliUNKNOWN 2011 AISF Single Topic Group
May 9, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J GavaldàM Cuenca-Estrella
May 26, 2015·Annals of Medicine and Surgery·Emad Hamdy GadAhmed Alshawadfy Sherif
Jun 28, 2011·Revista iberoamericana de micología·Guillermo Quindós
Dec 9, 2016·Expert Opinion on Drug Safety·Ioannis KyriakidisAndreas H Groll
Dec 14, 2018·Journal of Fungi·Nikolaos Spernovasilis, Diamantis P Kofteridis
Jan 2, 2021·World Journal of Gastroenterology : WJG·Alberto FerrareseMarco Senzolo
Jul 17, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Emily SartainAlice Gray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
E G PlayfordJ C Craig
World Journal of Hepatology
Fabian A Romero, Raymund R Razonable
© 2022 Meta ULC. All rights reserved